Fig. 2.

Scale for the Assessment of Negative Symptoms total score, by treatment and week. The mixed model analysis of covariance treatment × week interaction, with time treated as a continuous variable, was statistically significant (F = 5.61, df = 1,40.3, P = .023), supporting the existence of an increasingly large treatment difference favoring rasagiline. In the rasagiline group, n = 26 participants for all weeks. In the placebo group, n = 28 at weeks 0 and 4, n = 25 at week 8, and n = 23 at week 12.